CASE STUDY
33% REVENUE GROWTH WITH NAMED PATIENT PROGRAM
Case Studies > 33% Revenue Growth with Named Patient Program
SITUATION
U.S. manufacturer was launching their first product, an oral oncolytic for a rare sub-indication.
​
Forecast in the U.S. was ~ 500 patients.
​
Challenged to increase revenue potential for the brand.
APPROACH
Archbow consultant recognized the opportunity for a Named Patient Program (NPP) in EU & ROW markets.
​
Identified & vetted a vendor with EU & ROW capabilities.
​
Established protocol to import product, sell in ex-U.S. markets, collect & report AEs consistently, and communicate with HCPs.
RESULTS
By end of year 1, 1/3 of all product sales occurring outside of U.S.
​
Distribution eventually expanded to multiple markets, including EU, Asia, & South America.
​
All NPP sales counted toward U.S. revenue (top line).
​
Leveraged market & HCP knowledge to ensure smooth transitions to commercial operations as product was approved in ex-U.S. markets.